ClinicalTrialsFinder

Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium)

Nashville, Tennessee, United States

1 recruiting

Showing 1–1 of 1 trials

Recruiting
Phase 1Phase 2

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

Non-small Cell Lung Cancer (NSCLC)
Pierre Fabre Medicament171 enrolled16 locationsNCT06567015